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CSF BIOMARKER LEVELS OF Aß40 AND TAU/Aß 42 COR-
RESPOND TO NEUROPSYCHOLOGICAL OUTCOME IN
CHRONIC TBI PARTICIPANTS
Ava Puccio, Milos Ikonomovic, Sue Beers, Kathryn Edelman, Steven
Benso, Yuefang Chang, Walter Schneider, James Mountz, David
Okonkwo
University of Pittsburgh, Neurosurgery, Pittsburgh, USA
Objectives: Traumatic brain injury (TBI) involves axonal injury and
accumulation of pathological protein aggregates including amyloid-b
(Ab) and hyperphosphorylated tau (p-tau). Biomarker analysis of tau
and Ab concentrations in cerebrospinal fluid (CSF) may be an ob-
jective marker of cognitive status after TBI. The goal of the current
study was to analyze tau and Ab 40–42 in a cohort of military and
civilian participants with chronic deficits secondary to TBI, and cor-
relate neuropsychological outcome data with concentrations of tau
and Ab42 measured in CSF from the same subjects.
Methods: 19 chronic TBI participants ( > 6 months from injury; 16
males, mean age 41yrs, 8 military veterans and 11 civilians) underwent
lumbar puncture as well as neuropsychological testing. CSF was ana-
lyzed for concentrations of total tau, Ab1-42 (Ab42) and Ab1-40 (Ab40)
by ELISA, and tau/Ab42 ratio was calculated. The neuropsychological
test battery included measures of memory, processing speed and exec-
utive function: California Verbal Learning Test-II (CVLT) Short and
Long Delay Free Recall (SDFR, LDFR), Wechsler Adult Intelligence
ScaleWorkingMemory Index (WAIS IV) andTrailMakingTest Part A/B.
Nonparametric correlation (Spearman rho, q) was used to relate CSF
levels to neuropsychological data, controlling for age.
Results: CSF tau/Ab42 ratio was inversely associated with Trails B
(Spearman p > -0.49, p< 0.047). CSF Ab40 concentration was in-
versely correlated with CVLT SDFR and LDFR (Spearman p > -0.51,
p < 0.032; p > -0.50, p< 0.034, respectively). There were no signifi-
cant correlations between CSF biomarker levels and WAIS neu-
ropsychological measures.
Conclusions: In chronic TBI, neuropsychological outcome on
measures of memory and executive function (CVLT and Trails B)
corresponded to CSF biomarkers of tau and Ab concentrations. Ad-
ditional studies with a larger cohort of TBI participants are needed to
draw meaningful conclusions. The use of CSF biomarkers in ongoing
studies will allow us to test more specific hypotheses regarding the
link between TBI and chronic neurodegenerative conditions such as
chronic traumatic encephalopathy.
Keywords: chronic TBI, amyloid B, tau, neuropsychological outcome
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SGP130 MODERATES THE RELATIONSHIP BETWEEN
CHRONIC IL-6/SIL-6R COMPLEX IN DIFFERENTIATING
OUTCOME AFTER SEVERE TBI
Prerna Ranganathan1, Raj Kumar1, Amy Wagner1,2
1University of Pittsburgh, Department of Physical Medicine and Re-
habilitation, Pittsburgh, USA
2University of Pittsburgh, Safar Center for Resuscitation Research,
Pittsburgh, USA
The secondary injury response after traumatic brain injury (TBI) is
characterized by an acute innate immune response. While research has
focused on acute neuroinflammatory markers, our previous work sug-
gests sub-acute and chronic peripheral inflammatory markers influences
long-term global outcomes. Specifically, pro-inflammatory mediators,
including interleukin 6 (IL-6), 2 weeks to 3 months post-injury, were
associated with worse global outcomes at 6 and 12 months. Further, the
relationship between IL-6 and its soluble receptor, sIL-6R, facilitates a
signaling cascade predisposing individuals to a chronic inflammatory state;
in contrast soluble gp130 (sgp130), a potent IL-6 inhibitory transmem-
brane protein, moderates this relationship. To date, no clinical or experi-
mental TBI study has examined the association between IL-6/sIL-6R and
sgp130. The objective of this study was to evaluate relationships between
serum IL-6, sIL-6R, and sgp130 in the subacute period post-injury for
N=100 individualswith severeTBI.Monthly ratioswereproduced for IL-6:
sIL-6R and sgp130:sIL-6R, and IL-6 levels were quartiled using
levels from samples collected up to 3 months post-injury. Six-month
GOS scores were dichotomized to reflect poor (GOS = 2/3) vs. good
(GOS = 4/5) outcome. Bivariate analysis showed significant differ-
ences in sIL-6R by GOS group (p =<0.0001), where higher sIL-6R
levels were associated with poor outcome. sgp130:sIL-6R ratios also
significantly differed by GOS group (p = 0.0034), where lower ratios
were associated with poor outcome. A multivariate logistic regression
model including age, IL-6, sgp130:sIL-6R, and a sgp130:sIL-6R*IL-6
resulted in a significant interaction (OR = 5.527, p= 0.0047) in pre-
dicting 6-month outcome. The interaction suggests sgp130:sIL-6R
ratios influence global outcome by attenuating the IL-6/sIL-6R com-
plex, resulting in higher IL-6 levels. These results suggest the pref-
erential binding of sgp130 to sIL-6R selectively blocks progression of
inflammation through the inhibition of IL-6 signaling by the sIL-6R
after severe TBI. This work has novel implications for understanding
how sgp130 potentially serves as a modifiable target for prevention
and/or resolution of chronic inflammation post-TBI. Support: DoD-
W81XWH-071-0701; NIDILRR-90DP0041; R49-CCR323155.
Keywords: chronic inflammation, traumatic brain injury, innate
immunity, interleukin 6, sgp130
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PHARMACOLOGICAL MRI TO PROBE NMDA-MEDIATED
CIRCUIT CHANGES IN THE IMMATURE RAT AFTER FPI
Saman Sargolzaei1, YanCai1, Naomi SantaMaria2, Christopher C.Giza1,
Neil G Harris1
1UCLA, Neurosurgery, Los Angeles, USA
2Caltech, Pasadena, USA
Hippocampal lateral fluid percussion injury (LFPI) has been previously
correlated with memory and recognition deficits in developing rats and
dysfunction of glutamatergic neurotransmission via the N-methyl-D-
aspartate receptor (NMDAR), is a plausible factor. Protein expression
studies have confirmed a downregulation of NMDAR protein after ex-
perimental traumatic brain injury (TBI). To study the dynamics of
NMDARs in vivo, and their role in memory-related network dysfunction
after developmental TBI, we acquired pilot pharmacological magnetic
resonance imaging (phMRI) data at day 4 following injury (n= 6) or sham
(n= 4) of post-natal day-19 rats. This included a 5 minute baseline Cer-
ebral Blood Volume (CBV) enhanced imaging (7T Bruker spectrometer
using a single-shot, gradient-echo sequence, echo/repetition time: 20/
1000ms, 300 repetitions, 128 · 128 matrix, 30 · 30mm field-of-view
and 1mm slice-thickness) followed by systemic injection of 30mg/kg
DCS/ Saline in a 1 · 4 experimental design. Image acquisition con-
tinued 15 minutes post-injection. After typical preprocessing of time-
series data and standard space registration, Region of Interest (ROI)
based rCBV response analysis (pre vs. post drug challenge) was then
performed for five brain regions identified in a prior study as the
memory and recognition circuit, Prefrontal Cortex (PFC); Hippo-
campus (Hip); Thalamus (Tha); Perirhinal (PRh) and Entorhinal (Ent)
cortex. No significant changes in regional CBV signal were observed
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in control animals following the saline injection. Regional CBV
percent signal changes showed DCS-modulated network activation
(PFC: +2.29; Ent: +2.64; Hip: +3.46; Prh: +3.05; Tha: +2.99) in sham
control rats. Injured brain responses to the DCS challenge were in
agreement with our hypothesis of injury induced hippocampal neural
network irregularities (PFC: +0.85; Ent: +0.20; Hip: 0.90; Prh: +1.12;
Tha: +1.34). Perceived NMDAR-modulated responses were then fed
into a multivariate Granger causality analysis which also confirmed
the existence of significant (p < 0.01) changes in the DCS-mediated
hippocampal neural network between injury and sham.
Funding: R01NS27544, R01NS091222, UCLA Easton Labs for
Brain Injury, UCLA Steve Tisch BrainSPORT program, UCLA BIRC.
Keywords: Pharmacological MRI, Developmental TBI, NMDA
receptor, D-Cycloserine, Bain Connectivity Network
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ASSOCIATION OF RELEASED TISSUE FACTOR WITH
ELEVATED D-DIMER AS A SERUM BIOMARKER OF
TRAUMATIC BRAIN INJURY
Eiichi Suehiro1, Yuichi Fujiyama1, Miwa Kiyohira1, Yukari Motoki2,
Junzo Nojima2, Michiyasu Suzuki1
1Yamaguchi University Graduate School of Medicine, Department of
Neurosurgery, Ube, Japan
2Yamaguchi University Graduate School of Medicine, Faculty of
Health Science, Department of Laboratory Science, Ube, Japan
Objective: Recently, D-dimer blood levels were reported as a bio-
marker for the outcome of traumatic brain injury (TBI) patients.
However, the mechanisms that trigger elevated D-dimer blood levels
in TBI remain unclear. The purpose of this study was to evaluate the
reliability of D-dimer as a biomarker of TBI and to determine the
mechanisms involved in regulating its blood levels.
Methods: Nine patients with moderate to severe (Glasgow Coma
Scale score 3-13) isolated TBI were admitted and evaluated at our
hospital between May 2013 and June 2014. We collected blood samples
from systemic arteries on arrival in the emergency room and at 1, 3, 5,
7, and 14 days after injury. The plasma levels of neuron specific enolase
(NSE), D-dimer, and soluble tissue factor were measured.
Results: The plasma levels of NSE (33.4 ng/ml: normal value less than
12.0 ng/ml) and D-dimer (56.1lg/ml: normal value less than 1.0lg /ml)
were elevated on admittance and declined but were still elevated onDay 1
after injury. A significant correlation between NSE and D-dimer was seen
on admittance (R= 0.727, p= 0.026) and on the following days (R=0.694,
p< 0.001). Furthermore, a significant correlation between soluble tissue
factor and D-dimer was seen on admittance (R= 0.803, p= 0.009).
Conclusion: The level of blood D-dimer accurately reflected the
degree of brain damage indicated by NSE levels. Our data suggest that
the release of tissue factor induced by brain damage may activate the
coagulation cascade leading to elevation in D-dimer levels.
Keywords: traumatic brain injury, coagulopathy, biomarker
A06-14
ASTROGLIAL CELL WOUNDING BIOMARKER ALDOLASE
C IS ROBUSTLY ELEVATED IN MILD TBI PATIENTS
Timothy Van Meter1, Julia Halford2, NaZanin Mirshahi1, Albert
Chong2, Gerry Shaw3, Ronel Veksler4, Stefania Mondello5, TimMeier6,
Andrew Mayer7, Alon Friedman4, Frederick Korley8, Ina Wanner2
1ImmunArray, Program of Neurological Diseases, Richmond, VA, USA
2UCLA, Semel Institute, Los Angeles, CA, USA
3Encor Biotechnology, Gainesville, FL, USA
4Dalhousie University, Dept Medical Neuroscience, Halifax, Nova
Scotia, Canada
5Messina University, Dept Biomedical Science, Messina, Italy
6Medical College of Wisconsin, Dept Neurosurgery, Milwaukee, WI,
USA
7Mind Research Network, LRRI, Albuquerque, NM, USA
8University of Michigan Medical School, Dept Emergency Medicine,
Ann Arbor, MI, USA
Diagnostic monitoring of mild traumatic brain injury (mTBI) re-
quires robust biomarkers for precise, sensitive, objective assessment.
We recently identified Aldolase C (ALDOC) as a protein released
from acutely traumatized astrocytes in vitro (Levine et al., 2016).
GFAP release and proteolysis was associated with delayed cell
death, dependent on injury severity (Halford et al., accepted). The
current study examined ALDOC and GFAP levels in clinical sam-
ples after TBI. Healthy controls, mTBI, severe TBI and athletic
cohorts were studied in replicate electrochemiluminescence-based
ELISAs and compared with detectable protein bands in standardized
immunoblotting assays. Rank Sum, permutation and paired T-tests
were used to measure significant differences between cohorts. Stu-
dies demonstrated the C-isoform specificity of the antibodies and
showed CNS-specific expression. Both assays confirmed ALDOC
elevation after TBI compared to healthy controls (all reported
comparisons were significant at a = 0.05). A cohort of Italian mTBI
patients showed serum ALDOC elevation irrespective of CT-status,
while GFAP levels rose only in CT+ mTBI. In HeadSMART mTBI
patients, ALDOC was significantly elevated versus healthy controls.
ALDOC levels rose significantly in concussed NCAA athletes after
injury, versus controls and non-concussed players. In Israeli football
players, ALDOC elevation, but not GFAP, was detected in con-
cussed players versus controls. ELISA testing and immunoblotting
for GFAP breakdown-products found no GFAP elevation in either
athlete study despite elevation in severe TBI and some mTBI pa-
tients. Overall, multiple mTBI cohorts of different age, athletic
groups, and geographical location support ALDOC as a robust bio-
marker for mTBI.
Keywords: Biomarker, GFAP, ALDOC, Athlete, mild TBI
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EXAMINING ADAPTIVE IMMUNE RESPONSE AND
RELATIONSHIPS BETWEEN IL-7 AND ANTI-PITUITARY/
HYPOTHALAMIC AUTOANTIBODIES AFTER SEVERE-TBI
Sushupta Vijapur1, Prerna Ranganathan1, Raj Kumar1, Zhihui Yang4,
Penelope Morel3, Kevin Wang4, Amy Wagner1,2
1University of Pittsburgh, Department of Physical Medicine and Re-
habilitation, Pittsburgh, USA
2University of Pittsburgh, Safar Center for Resuscitation, Pittsburgh, USA
3University of Pittsburgh, Department of Immunology, Pittsburgh, USA
4University of Florida, Department of Psychiatry, Gainesville, USA
Traumatic brain injury (TBI) is associated with long-term compli-
cations, including persistent hypogonadotropic hypogonadism
(PHH), which our studies suggest a link to autoimmunity. Auto-
antibodies (AAb) to the pituitary (APA) and hypothalamus (AHA)
are present up to one-year following TBI and reduced IgM AAb in-
creases PHH-risk among men with TBI. Adaptive immunity, including
interleukin 7 (IL-7) production, may promote brain tissue-specific AAb
A-28
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